Engrail Therapeutics
Acquiring, developing and commercializing transformative medicines.
Launch date
Employees
Market cap
-
Enterprise valuation
€571—856m (Dealroom.co estimates Mar 2024.)
San Diego California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$32.0m | Series A | ||
$32.0m | Series A | ||
* | $157m | Series B | |
| Total Funding | €201m | ||
Related Content
Recent News about Engrail Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Engrail Therapeutics
Edit
ACQUISITION by Engrail Therapeutics Feb 2021